Connect with us

Hi, what are you looking for?

Investing

Agreements to Establish Indonesian-Based Seaweed Business and Capital Raising

Further to previous announcements made by the Board of BPH Global Ltd (ASX: BP8) (Company) regarding the Company’s strategic review of its seaweed operations and the expansion of its R&D operations to include the extraction of minerals and gases for use in the battery and energy industries, the Board is pleased to announce that the Company has entered into a binding term sheet to acquire Indonesian-based seaweed assets and for the joint development of an Indonesian- based seaweed business.

Highlights

Establishment of Indonesian-based, seaweed focused businessBP8 to incorporate 100% owned subsidiary in IndonesiaJoint venture partners to contribute assets to the ventureFocus on commercialisation opportunities based on sales of raw seaweed and seaweed-based and infused productsParticular focus on development of seaweed-based bio stimulant products for sale into the Indian marketAUD100,000 placement by a venture partner to support development of the business

Term Sheet

On 22 September 2024, the Company entered into a legally binding term sheet (Term Sheet) with Singapore and Indonesian-based joint venture partners Messrs Rajiv Ramnarayan and Deepak Jha and PT Mitra Agro Global an Indonesian company (together the JV Partners) for the acquisition by the Company of Indonesian-based assets owned by the JV Partners (Assets) and the incorporation by the Company of a wholly owned Indonesian subsidiary (BP8 Indonesia). The JV Partners have undertaken preliminary activities in developing seaweed sourcing in Indonesia and identifying potential sales channels for the seaweed supply and are undertaking preliminary R&D into a seaweed bio-stimulant project.

The bio-stimulant project is targeting development of an agricultural-based product which is an additive to crops used in the production of food products. The bio-stimulant seeks to increase nutrient availability and uptake in those food sources so as to optimise Traditional Chinese Medicine outcomes. The JV Partners have developed a relationship with an Indian-based holder of intellectual property relating to bio-stimulant technology (Bio-stimulant IP} and will assist the Company in its endeavours to obtain a licence to use that intellectual property.

BP8 considers that it can combine its own seaweed sector intellectual property and resources with the JV Partners’ activities and the Assets to develop a joint venture project in Indonesia focused on:

seaweed cultivation, sourcing and sales, andR&D into a seaweed bio-stimulant project and its commercialisation.

Click here for the full ASX Release

This post appeared first on investingnews.com

World biggest companies

Learn Trading With Online Courses, Classes, & Lessons

You May Also Like

Investing

2023 was a relatively lackluster year, silver largely traded on volatility between US$22 and US$25 per ounce. The white metal started 2024 with less...

Latest News

Dong’s experience, both as head of the People’s Liberation Army Navy (PLAN) as well as operational assignments in the Chinese military’s Eastern and Southern...

Investing

The US was one of the world’s top silver producers in 2023, recording output of 1,000 metric tons (MT). While that’s far below first-place...

Investing

The Canadian pharmaceutical market is the eighth largest in the world and accounts for 2.2 percent of the global prescription drug market. But what...

Disclaimer: GreatWallStreetPublisher.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


Copyright © 2024 GreatWallStreetPublisher.com